Przejdź do zawartości
Merck

[Evidence-based drug therapy for male infertility].

Der Urologe. Ausg. A (2008-11-18)
G Haidl, H C Schuppe, F M Köhn, C Leiber
ABSTRAKT

Evidence-based drug therapy for male infertility is often difficult because 30% of all cases of male infertility are classified as idiopathic, and another 30% need surgical treatment. Without knowledge of the underlying pathology, there is no foundation for a specific and causal treatment. Most of the currently used drug therapies are empirical at best; moreover, many of the studies on drug treatment for male infertility do not fulfill the required standards of evidence-based medicine (randomized, prospective, placebo-controlled), and the statistical endpoints used (sperm quality, pregnancy rate, baby take-home rate) are not uniform. This article, which is based on a literature survey and the current guidelines concerning drug therapy for male infertility, covers the most common treatment options. Regarding the currently insufficient scientific data for drug therapy and dietary supplements on male infertility, there is a demand for critical indications that take into consideration the possible side effects and the treatment costs. In the case of insufficient drug therapy for male infertility, reproductive medicine seems to be promising.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Testosterone decanoate, European Pharmacopoeia (EP) Reference Standard